In 2014, Science called GDF11 a breakthrough—a protein in young blood that reverses aging. Then an independent lab found the opposite. A decade later, the field has not recovered. This is what a replication crisis looks like from the inside.

The GDF11 story is a cautionary tale about what happens when a spectacular finding meets the slow, uncomfortable process of replication. In 2013, Amy Wagers and colleagues at Harvard reported that GDF11 declines in aging blood. They claimed that restoring it to youthful levels could reverse heart enlargement in old mice. The following year, companion papers showed similar rejuvenation in skeletal muscle and the brain. Science magazine named it one of the top breakthroughs of 2014. The media narrative was irresistible: young blood contains a factor that reverses aging, and we had found it.

Then in 2015, a team at Novartis led by David Glass published a comprehensive challenge. Using more specific assays, they found that GDF11 increases with age, not decreases. The antibody and aptamer used in the Harvard studies cross-reacted with myostatin—a closely related protein that is a known muscle growth inhibitor. When Novartis gave recombinant GDF11 to aged mice, the animals lost muscle mass. A separate group confirmed that GDF11 does not rescue cardiac hypertrophy. Another study found that high-dose GDF11 causes cachexia and death in mice.

The field fractured. Some labs found results consistent with the original claims, particularly in neurogenesis. Others confirmed the Novartis findings. The question of whether GDF11 increases or decreases with age remains contested a decade later. A 2025 study in Nature Communications added a new wrinkle. In over 11,000 patients, low levels of activated GDF11 subforms predicted heart attacks and death. That suggests the story is more complex than either camp acknowledged.

This article is not here to pick a winner. It is here to lay out what happened, what the evidence actually shows for each tissue, and why this compound carries the only "Thin Ice" verdict in Cluster C. GDF11 is also not a peptide—it is a ~25 kDa protein that appears on a peptide research site because the anti-aging community discusses it alongside peptides. That classification matters, and this article explains why.

Quick Facts: GDF11 at a Glance

What Is GDF11?

Pronunciation: jee-dee-eff-eleven

GDF11 is not a peptide. It is a protein—a full-sized, 25-kilodalton disulfide-linked homodimer belonging to the TGF-beta superfamily of signaling molecules. This distinction matters because proteins and peptides behave differently in the body: they have different pharmacokinetics, different delivery requirements, and different manufacturing constraints. GDF11 cannot be absorbed through the skin, taken orally, or delivered intranasally. It requires systemic injection. Calling it a peptide would mislead readers about its practical use.

GDF11 appears on this site because the anti-aging community discusses it alongside peptides. When the Harvard parabiosis studies made headlines in 2013–2014, GDF11 became part of the longevity conversation that also includes compounds like BPC-157, epitalon, and SS-31. Peptide vendors sell recombinant GDF11. Biohacking forums discuss it in peptide threads. The compound belongs to this conversation even though it does not belong to this molecular class.

The biological story of GDF11 is inseparable from its near-twin: myostatin (GDF8). The two proteins share 89–90% amino acid sequence identity in their mature domains. They bind the same receptors. They activate the same downstream signaling pathway (SMAD2/3). And in the blood tests that launched the GDF11 revolution, they could not be reliably distinguished from each other. That measurement problem is the seed of the entire replication crisis.

Origins and Discovery

The Parabiosis Breakthrough (2013–2014)

The GDF11 story begins with heterochronic parabiosis—a technique where the circulatory systems of a young and an old mouse are surgically joined. When old mice receive young blood, they show remarkable improvements: better heart function, stronger muscles, more new brain cells. The question that dominated aging research in the early 2010s was: what is in young blood that makes this happen?

Amy Wagers and colleagues at Harvard believed they had found the answer. In 2013, Loffredo et al. published a Cell paper (PMID 23663781) reporting that GDF11—a member of the TGF-beta superfamily—declines in aging blood, and that restoring it to youthful levels reversed cardiac hypertrophy in old mice within four weeks.

In 2014, two companion papers in Science extended the claim. Sinha et al. (PMID 24797481) showed GDF11 restored skeletal muscle regeneration in aged mice. Katsimpardi et al. (PMID 24797482) showed GDF11 promoted neurogenesis and vascular remodeling in the aging brain. Science named the "young blood" research—with GDF11 as the central molecule—a top breakthrough of 2014. The media coverage was extraordinary. "Protein in young blood" became a shorthand for the possibility that aging could be reversed with a single molecule.

The Replication Crisis (2015–2016)

David Glass and colleagues at Novartis published a direct challenge (PMID 26001423) in Cell Metabolism. Their findings contradicted the Harvard results on three fundamental points:

First, using a newly developed GDF11-specific immunoassay, they found that GDF11 increases with age in rats and humans—the opposite of the Harvard claim. The original studies had used an antibody and a SOMAmer aptamer that cross-reacted with myostatin.

Second, because GDF11 and myostatin share 89–90% sequence identity and bind the same receptors, the "declining GDF11" signal in the Harvard studies may have been predominantly myostatin—a known muscle growth inhibitor whose decline with age would produce exactly the opposite interpretation.

Third, when Novartis administered recombinant GDF11 to aged mice, the animals experienced muscle wasting and impaired regeneration—the opposite of the Harvard claim.

The same year, Smith et al. (PMID 26383970) found that GDF11 does not rescue cardiac hypertrophy in aged mice and may actually induce it in vitro. In 2017, Zimmers and colleagues (PMID 28647906) showed that exogenous GDF11 causes cachexia and death in mice at higher doses.

Mechanism of Action

TGF-beta Superfamily Signaling

GDF11 is secreted as a ~55 kDa pro-protein. Proteolytic cleavage releases the mature ~25 kDa homodimer, which binds type II activin receptors (ActRIIA, ActRIIB). This recruits type I receptors (ALK4, ALK5), which phosphorylate SMAD2 and SMAD3. The phosphorylated SMADs translocate to the nucleus and regulate gene transcription.

This is the same signaling pathway used by myostatin. The two proteins are functionally redundant at the receptor level. Any assay that measures downstream SMAD2/3 phosphorylation cannot distinguish between GDF11 and myostatin activation.

The Myostatin Identity Problem

Myostatin (GDF8) is one of the best-studied proteins in muscle biology. It is a negative regulator of muscle growth—myostatin-knockout mice are massively muscular. Pharmaceutical myostatin inhibitors are in clinical development for muscle wasting diseases. The idea that GDF11, a 90% identical protein that binds the same receptors and activates the same signaling cascade, would have the opposite effect—promoting muscle growth—was always biologically implausible. The Novartis replication failure confirmed this implausibility with data.

What GDF11 Actually Does (Developmental Biology)

GDF11 has well-established roles in embryonic development: anterior-posterior body axis patterning, kidney organogenesis, skeletal formation, and pancreatic beta cell differentiation. GDF11-knockout mice die at birth with absent kidneys, displaced hindlimbs, and anterior homeotic transformations. The protein is essential for development. Whether it has a meaningful post-developmental role in adult tissue maintenance or aging is the contested question.

The 2025 Subform Discovery

A Nature Communications study (2025) measured activated GDF11/8 subforms in over 11,000 patients and found that low levels strongly predicted cardiovascular events (HR 0.43) and all-cause mortality (HR 0.33). This suggests the relationship between GDF11 and aging may depend on which form—pro-form, latent, or activated—is measured, and that the binary "good vs. bad" framing may be too simple.

Key Research

The Harvard Papers (2013–2014)

Loffredo et al., Cell, 2013 (PMID 23663781). Heterochronic parabiosis reversed cardiac hypertrophy in aged mice. Identified GDF11 as a circulating factor that declines with age. Recombinant GDF11 administration recapitulated the cardiac benefits. This is the paper that launched the GDF11 narrative.

Sinha et al., Science, 2014 (PMID 24797481). GDF11 supplementation restored skeletal muscle regeneration in aged mice. Increased exercise endurance and strength. Corrected genomic instability in aged muscle stem cells.

Katsimpardi et al., Science, 2014 (PMID 24797482). GDF11 promoted vascular remodeling and neurogenesis in the aged brain. Improved olfactory discrimination. Proposed mechanism: systemic GDF11 acts on endothelial cells without crossing the blood-brain barrier.

The Novartis Replication Failure (2015)

Egerman et al., Cell Metabolism, 2015 (PMID 26001423). The pivotal challenge paper. Found: (1) GDF11 increases with age, not decreases; (2) the antibody and aptamer used by Harvard cross-react with myostatin; (3) recombinant GDF11 inhibits skeletal muscle regeneration and causes wasting. This paper redefined the field.

The Cardiac Replication Failure (2015)

Smith et al., Circulation Research, 2015 (PMID 26383970). Found no age-related pathological cardiac hypertrophy in 24-month mice. GDF11 had no effect on cardiac structure or function. In vitro, GDF11 induced hypertrophy—the opposite of the Loffredo claim.

The Cachexia Finding (2017)

Zimmers et al., 2017 (PMID 28647906). Exogenous GDF11 causes cardiac and skeletal muscle wasting and death in mice at higher doses. Dose-dependent muscle atrophy. This is the most alarming safety finding in the GDF11 literature.

The Neurogenesis Paradox (2021)

Mayweather et al., Molecular Brain, 2021 (PMID 34488822). Endogenous GDF11 in the adult brain is a neurogenesis inhibitor—depleting brain GDF11 increases neural progenitor proliferation. But exogenous systemic GDF11 appears to promote neurogenesis (Katsimpardi's finding). The paradox: brain-resident and circulating GDF11 may act on different cell populations through different mechanisms. Neurogenesis is the one domain where the original claims have some independent support, but the biology is more complex than "more GDF11 = more neurons."

The 2025 Human Outcome Data

Nature Communications, 2025. 11,609 patients at cardiovascular risk; 4,110 in the ARIC cohort. Low activated GDF11/8 subforms strongly predicted cardiovascular events (HR 0.43) and all-cause mortality (HR 0.33). Low GDF11/8 also predicted 8-year dementia risk (HR 0.66). This is the largest human GDF11 dataset and it complicates the narrative: if low GDF11 predicts death, the "GDF11 is harmful" position needs revision. But if high GDF11 causes muscle wasting, the "GDF11 is beneficial" position also has problems.

The Replication Crisis: A Detailed Accounting

This section exists because GDF11 is the most scientifically controversial compound on this site. The replication crisis is not a side story—it is the story. Understanding what went wrong, what remains contested, and what the current state of play is requires more space than a standard section, and Peptidings gives it that space.

The Measurement Problem

The root cause of the entire GDF11 controversy is an antibody. The Abcam anti-GDF11 antibody used in the original Harvard studies cross-reacts with myostatin. The SOMAmer aptamer used for proteomic profiling also binds both proteins. Because GDF11 and myostatin share 89–90% sequence identity in their mature domains, any immunoassay or affinity reagent designed for one will detect the other unless extraordinary specificity is achieved.

When the Harvard team measured "GDF11" declining with age, they were likely measuring the sum of GDF11 and myostatin. Since myostatin is far more abundant in circulation than GDF11, the signal was dominated by myostatin. If myostatin declines with age (which is debated but plausible in some mouse strains), the "GDF11 decline" signal was an artifact.

The Tissue-by-Tissue Scorecard

Heart: Not replicated. Smith et al. (2015) found GDF11 does not rescue cardiac hypertrophy. In vitro, it induced hypertrophy. The cardiac rejuvenation claim is the most thoroughly challenged.

Muscle: Contradicted. Novartis showed GDF11 causes muscle wasting. Zimmers showed it causes cachexia at higher doses. The muscle claim is the most thoroughly refuted. This is biologically consistent—a 90% myostatin homolog should inhibit muscle growth.

Brain/Neurogenesis: Partially supported. The Katsimpardi findings have some independent replication. But the Mayweather 2021 study showed that endogenous brain GDF11 actually inhibits neurogenesis—the opposite of what you would expect if GDF11 were a universal rejuvenation factor. The proposed resolution: systemic GDF11 may act on brain vasculature (endothelial cells), improving blood flow and indirectly promoting neurogenesis, while brain-resident GDF11 acts directly on neural progenitors to suppress them. If true, this means GDF11 is not a direct neurogenesis promoter but an indirect vascular mediator—a very different claim.

The Commercial Dimension

Elevian Therapeutics was founded on the Harvard GDF11 patents. The company raised $40 million in a 2021 Series A and initiated Phase 1 trials for stroke recovery in ~2023. Whether GDF11 has therapeutic value in stroke—where vascular remodeling is the relevant mechanism, not muscle regeneration—is a more defensible hypothesis than the original anti-aging claim. But no clinical efficacy data has been published.

Where the Field Stands (2026)

The original "GDF11 is a rejuvenation factor" narrative has largely collapsed for muscle and heart. The neurogenesis data survives with significant mechanistic caveats. The 2025 human outcome study reopens the question of whether GDF11 subforms have clinical relevance, but through an entirely different lens than the original parabiosis story. The field has not reached consensus. It may not for years.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

No completed human interventional trial has tested GDF11 for any anti-aging indication. The human evidence landscape consists of one ongoing clinical program and one large observational study—neither of which tests the rejuvenation hypothesis that made GDF11 famous.

Elevian Phase 1 Stroke Trial (~2023–ongoing)

Elevian Therapeutics, founded on Harvard's GDF11 patents, initiated a Phase 1 trial for stroke recovery. The target is vascular remodeling after ischemic stroke—not anti-aging, not muscle regeneration, not cardiac rejuvenation. This is a deliberate pivot: the vascular mechanism is the one domain where the original data has some independent support, and stroke recovery does not require the contested muscle or cardiac claims. No results have been published. This will be the first human dosing data for recombinant GDF11 when it is released.

The 2025 Human Outcome Study (Nature Communications)

The largest human GDF11 dataset: 11,609 patients at cardiovascular risk and 4,110 in the ARIC cohort. Researchers measured activated GDF11/8 subforms (using assays that distinguish GDF11 from myostatin more reliably than the original Harvard methods). Key findings: low activated GDF11/8 subforms strongly predicted cardiovascular events (HR 0.43), all-cause mortality (HR 0.33), and 8-year dementia risk (HR 0.66). This is observational—it shows association, not causation. But it complicates both the "GDF11 is harmful" narrative (Novartis) and the "GDF11 is rejuvenating" narrative (Harvard), suggesting the biology depends on which subform is measured and in what context.

Self-Experimentation Reports

One notable self-experimenter (Steve Perry) has reported positive outcomes—improved blood pressure, heart rate variability, grip strength, memory, and reported epigenetic age reversal—in an uncontrolled, unblinded personal experiment running since 2014. Perry has recruited over 100 volunteers but no controlled data has been published. These reports are uninterpretable without controls—they cannot distinguish GDF11 effects from placebo, lifestyle changes, or other interventions.

What Would Need to Happen for Human Evidence to Emerge

The Elevian stroke trial is the near-term gate. If it demonstrates safety and any efficacy signal, the anti-aging question may eventually be testable—but through an entirely different lens than the original "rejuvenation factor" framing. A controlled trial specifically testing GDF11 for any aging endpoint would require: resolution of the optimal dose (the Zimmers data shows high doses cause cachexia in mice), selection of appropriate subform, and identification of a measurable primary endpoint. Given the replication crisis, funding such a trial would be difficult.

Safety, Risks, and Limitations

Muscle Wasting and Cachexia

The most alarming safety finding: exogenous GDF11 causes dose-dependent muscle wasting in mice (Egerman 2015, PMID 26001423) and cachexia and death at higher doses (Zimmers 2017, PMID 28647906). For a compound marketed as a rejuvenation factor, this is a fundamental safety signal. The mechanism is consistent with GDF11's homology to myostatin—a known muscle atrophy inducer.

Cardiac Risk

GDF11 may induce rather than reverse cardiac hypertrophy (Smith 2015, PMID 26383970). The cardiac safety profile in humans is entirely unknown.

Protein Size and Delivery Risks

GDF11 is a ~25 kDa protein. Unlike small peptides (1–5 kDa), large proteins injected subcutaneously or intravenously carry risks of immunogenicity, aggregation, and immune complex formation. No human immunogenicity data exists.

Developmental Signaling

GDF11 is essential for embryonic patterning. Reactivating developmental signaling pathways in adults carries theoretical risks of disrupting tissue homeostasis, including potential effects on stem cell quiescence, wound healing, and cancer biology.

Quality Control

Commercial recombinant GDF11 varies in purity (85–95%+), expression system (E. coli vs. mammalian), and presence of affinity tags. Non-glycosylated E. coli-expressed GDF11 may have different biological activity than endogenous glycosylated GDF11. Self-experimenters cannot verify product identity or purity.

Legal and Regulatory Status

GDF11 is not FDA-approved for any indication. Elevian Therapeutics is the only company with an active regulatory pathway (Phase 1 for stroke recovery, initiated ~2023). No anti-aging trial is planned or registered.

Recombinant GDF11 is available from research suppliers (R&D Systems, Abcam, ProSpec, others) as a research chemical. It is also available from gray-market peptide vendors. It is not explicitly banned from compounding pharmacies.

GDF11 is not listed on the WADA 2025–2026 Prohibited List.

Research Protocols and Formulation Considerations

Published animal protocols: - Harvard cardiac study: Recombinant GDF11 IP injection, daily for 30 days (aged mice) - Novartis replication: Recombinant GDF11 IP/SC injection, variable schedules - Zimmers cachexia study: Higher-dose recombinant GDF11, dose-dependent muscle wasting

Storage: Standard protein storage: −20°C to −80°C (−4°F to −112°F) for lyophilized powder. Reconstituted solutions at 2–8°C (35–46°F), use within days.

Critical note: GDF11 is a ~25 kDa protein requiring cold-chain handling. It is not as stable as small peptides. Reconstituted protein degrades faster and is more sensitive to temperature, pH, and handling conditions.

Dosing in Published Research

Published research doses (all animal): - Harvard: ~0.1 mg/kg/day IP for 30 days (mice) - Doses above ~0.5 mg/kg have caused cachexia in mice

There is no established human dose for GDF11. The only human dosing data will come from the Elevian Phase 1 stroke trial, which has not published results.

Detailed Research Dosing Data (from published studies)

Key Notes on Research Dosing: - All dosing is expressed as mg/kg of body weight, which is standard for animal research. - A 20-gram mouse dosed at 1 mg/kg receives 20 micrograms of GDF11. - No dose-response studies systematically evaluated the effect of varying GDF11 doses from subtherapeutic to toxic levels. - The duration of treatment in most studies is short (2–4 weeks), which is insufficient to establish safety or assess long-term effects. - IV administration achieves systemic delivery rapidly; IP administration has slower absorption but avoids the need for venipuncture in rodents. - No studies have titrated GDF11 doses upward to identify a maximum tolerated dose or toxic threshold. - The doses used in research (1 mg/kg = approximately 0.02–0.05 mg per mouse) far exceed what any commercial GDF11 peptide product would deliver to humans, even at high self-administered doses—another reason why human translation is speculative.

Dosing in Self-Experimentation Communities

Community use of GDF11 is extremely limited. The compound is expensive, requires injection, and has a well-publicized replication crisis that has dampened enthusiasm.

One notable self-experimenter (Steve Perry) has reported positive outcomes—improved blood pressure, heart rate variability, grip strength, memory, and reported epigenetic age reversal—in an uncontrolled, unblinded personal experiment since 2014. Perry has recruited over 100 volunteers but no controlled data has been published. The emphasis on "dose is critical" from this community suggests that the therapeutic window, if one exists, is narrow—consistent with the Zimmers finding that higher doses cause cachexia.

No systematic adverse event reporting exists. The small user base and absence of controlled conditions make anecdotal reports uninterpretable.

Combination Stacks

Research into GDF11 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining GDF11 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

GDF11 is the compound that teaches you how science goes wrong—and how long it takes to figure that out. The original discovery was published in one of the world's top journals. It was named a breakthrough of the year. It launched a company. And the central claims have not survived a decade of attempted replication.

The original "rejuvenation factor" narrative has largely collapsed. The 2013 claim that GDF11 declines with age and that restoring it reverses aging was built on an assay that could not distinguish GDF11 from myostatin. Multiple independent labs using more specific methods found that GDF11 increases with age. The cardiac rejuvenation claim was not replicated. The muscle regeneration claim was directly contradicted—GDF11 causes muscle wasting. The "young blood reversal" story that made headlines was, at best, misattributed and, at worst, an artifact of measurement error.

The myostatin problem is not a footnote. It is the explanation. GDF11 and myostatin are 90% identical. They bind the same receptors. They activate the same signaling. Myostatin is a known muscle growth inhibitor. Expecting GDF11 to do the opposite was always biologically implausible. The Novartis data confirmed the implausibility with functional studies. The measurement problem—the antibody that could not tell them apart—was the seed of the entire false narrative.

Neurogenesis is the one survivor, and it is complicated. The Katsimpardi 2014 findings on brain rejuvenation have some independent support. But the Mayweather 2021 study showed endogenous brain GDF11 actually suppresses neurogenesis. The proposed resolution—systemic GDF11 acts indirectly via vascular remodeling, not directly on neurons—is plausible but transforms the claim from "GDF11 rejuvenates the brain" to "GDF11 might improve brain blood flow." Those are very different stories.

Exogenous GDF11 is demonstrably harmful at moderate-to-high doses. Muscle wasting at moderate doses (Egerman 2015). Cachexia and death at higher doses (Zimmers 2017). Possible cardiac hypertrophy induction in vitro (Smith 2015). For a compound marketed as rejuvenating, the safety profile in animal models is alarming. No human safety data has been published.

The 2025 human data reopens a door, but to a different room. The Nature Communications study showing that low activated GDF11 subforms predict cardiovascular events and mortality in 11,609 patients is the largest human GDF11 dataset. It complicates both the "GDF11 is bad" and "GDF11 is good" narratives. The biology may be subform-specific, context-dependent, and far more nuanced than the binary debate of the last decade.

Elevian is the only clinical bet, and it is not about anti-aging. The company targets stroke recovery—a vascular indication consistent with the neurogenesis/vasculature data. Phase 1 is ongoing. No anti-aging trial is planned. Even if stroke data is positive, the path to an anti-aging indication is measured in additional billions and decades.

Community self-experimentation is anecdotal and uninterpretable. One notable self-experimenter has reported positive outcomes in an uncontrolled setting. Over 100 volunteers have participated. No controlled data has been published. Given the animal data showing dose-dependent wasting, self-experimentation with GDF11 carries risks that are not merely theoretical.

Verdict Recapitulation

GDF11 earns Tier ~ because no standard tier can represent a replication crisis. The original evidence base was Tier 4 (preclinical animal data). But that preclinical evidence has been actively contradicted by multiple independent labs. A contradicted Tier 4 is worse than an unreplicated Tier 4—it is a compound where the positive data has been challenged and the negative data is arguably stronger.

GDF11 earns "Thin Ice"—the only red verdict in Cluster C—because the weight of evidence has shifted against the core claims. The cardiac rejuvenation was not replicated. The muscle regeneration was contradicted. The measurement that launched the narrative was flawed. Exogenous GDF11 causes muscle wasting and cachexia in animal models. One domain (neurogenesis) has partial support with significant caveats. And no human interventional data exists.

This does not mean GDF11 is scientifically uninteresting. The 2025 human outcome data suggests the biology is more complex than either camp has acknowledged. The Elevian stroke trial may produce meaningful results. And the story of how GDF11 went from breakthrough to replication crisis is itself valuable—it teaches readers what rigorous science looks like, including the uncomfortable parts.

For readers considering GDF11: this is the only compound on this site where the evidence actively argues against the most popular claims. The headlines from 2014 no longer reflect the state of the science. If you are using GDF11, you are not just ahead of the evidence—you are acting against the weight of the current evidence for the endpoints most people care about. Your eyes should not merely be open. They should be skeptical.

For readers considering GDF11, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source GDF11

Further Reading and Resources

If you want to go deeper on GDF11, the evidence landscape for longevity & anti-aging peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Longevity & Anti-Aging Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: GDF11 — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Loffredo et al., "Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy." Cell, 2013. —The original cardiac rejuvenation claim PubMed
2. Sinha et al., "Restoring Systemic GDF11 Levels Reverses Age-Related Dysfunction in Mouse Skeletal Muscle." Science, 2014. —The muscle regeneration claim PubMed
3. Katsimpardi et al., "Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors." Science, 2014. —The neurogenesis claim PubMed
4. Egerman et al., "GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration." Cell Metabolism, 2015. —The Novartis replication failure PubMed
5. Smith et al., "GDF11 Does Not Rescue Aging-Related Pathological Hypertrophy." Circulation Research, 2015. —The cardiac replication failure PubMed
6. Zimmers et al., "Exogenous GDF11 Induces Cardiac and Skeletal Muscle Dysfunction and Wasting." 2017. —The cachexia and death finding PubMed
7. Mayweather et al., "GDF11 Expressed in the Adult Brain Negatively Regulates Hippocampal Neurogenesis." Molecular Brain, 2021. —The neurogenesis paradox PubMed
8. Nature Communications, 2025. "Activated GDF11/8 Subforms Predict Cardiovascular Events and Mortality in Humans."—The 11,609-patient human outcome study
9. GDF11 and Aging Biology—Controversies Resolved and Pending. Journal of Cardiovascular Aging, 2024. *PMC 10793994*—Comprehensive review
10. Similar Sequences but Dissimilar Biological Functions of GDF11 and Myostatin. Experimental & Molecular Medicine, 2020.—Structural comparison of GDF11 and GDF8
11. Biochemistry and Biology of GDF11 and Myostatin. Circulation Research, 2017.—Receptor-level analysis of GDF11/myostatin redundancy
12. Elevian Therapeutics Series A announcement, PR Newswire, 2021.—$40M funding for Phase 1 stroke trials
13. Elevian 2025 publication: optimized rGDF11 dosing regimen for stroke and candidate biomarkers
14. Role of Growth Differentiation Factor 11 in Development, Physiology and Disease. Oncotarget, 2017. *PMC 5655313*
15. Recombinant GDF11 Promotes Recovery in a Rat Permanent Ischemia Model of Subacute Stroke. Stroke, 2025.—Elevian preclinical stroke data

---